Design and Characterization of Zolmitriptan Nanoparticle- Embedded Mouth Dissolving Films for Rapid Onset of Action

Read full text Summarise with VIRAT
Authors: K. Senthil kumar
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Zolmitriptan, a 5-HT receptor agonist, is a second-generation triptan prescribed for the treatment of migraine attacks, with and without an aura, and cluster headaches. Zolmitriptan is a basic compound and solubility increases with decreasing pH of the solution, and shows poor solubility at intestinal pH. It is classified as high soluble and low permeable drug (BCS class III) and exhibit a low oral bioavailability of about 40% due to extensive hepatic first pass metabolism. To overcome this limitation, the present study was undertaken to formulate mouth dissolving films (MDF) containing zolmitriptan nanoparticles to achieve rapid onset of action and enhanced buccal absorption of nanosized particles, thereby improving oral bioavailability by circumventing first pass metabolism. Nanoparticle were prepared using chitosan, a biocompatible biopolymer, by ionic gelation method involving Chitosan and STPP (Sodium Tripoly Phosphate). Formulated nanosuspensions were characterized for particle size, polydispersity index and zeta potential. The influence of formulation and process parameters was investigated.MDF were prepared by solvent casting method using zolmitriptan nanoparticles and HPMC as the film-forming polymer, and were found to possess desirable physico-mechanical properties. In vitro release studies showed that more than 90%of the drug was released within 3 minutes from both simulated salivary fluid and 0.1M HCl.Conclusively, the present study demonstrates the development of a potentially commercially viable MDF formulation of zolmitriptan nanoparticle, which may provide rapid drug release and faster therapeutic action in the management of migraine attacks.

Fields of Study & Subjects

Advanced Drug Delivery Systems Drug Solubulity and Delivery Systems Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
Journal of Pharmaceutical Sciences
Publication date
28 March 2026
Language
EN